Hosted on MSN
GeneSight Testing in 2026 Offers Flexible Ordering, Clear Coverage Rules, and Actionable Reports
In 2026, GeneSight testing allows both clinicians and patients to choose between in-office and at-home DNA collection, with clear insurance coverage criteria and capped self-pay costs. Its color-coded ...
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
YORK, Pa. — A simple cheek swab claims to give patients an individualized look at which medications are best suited for their mental health, based on their DNA. "There may be an issue where ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE ...
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results